SecOps

You may have missed

Tiziana Life Sciences plc: PDMR Dealing

Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215

MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis

Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate

Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)

error: Content is protected !!